PRTH-101,Pembrolizumab
Parthenon Therapeutics,merck
['solid tumor']
portfolio company parthenon therapeutics announces data at 's american association for cancer research annual meeting on prevalence of immune exclusion in solid tumors to support phase 1 clinical trial of its lead candidate prth-101. #aacr23 
Breakout Ventures invests in creative bioscience companies harnessing the power of cells and computation to scale solutions in human health and sustainability.